Antimicrobial resistance has emerged as a critical global health challenge, necessitating the discovery of new antibiotics. Cannabigerol (CBG) and cannabigerolic acid (CBGA) from Cannabis sativa have shown promising activity as antibacterial agents. In this work, a total of 26 CBG and CBGA derivatives (13 of each) featuring varied terpene chain lengths and substitution patterns were synthesized and characterized; of these, 20 are novel analogs. To determine their structure–activity relationships (SAR), we tested their antibacterial activity against Gram-positive bacterial strains, including Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), and vancomycin-resistant Enterococcus faecalis (VRE). Our results reveal that terpene chain lengths between 6 and 13 carbons show potent antibacterial activity with no detectable cytotoxicity toward mammalian cells. In addition, several CBG analogs exhibited minimum inhibitory concentrations (MICs) similar to the FDA-approved drug, daptomycin, against multiple Gram-positive strains. Comparing the antibacterial activities of different CBG and CBGA derivatives establishes the terpene moiety as a critical structural determinant for antibacterial potency in CBG and CBGA scaffolds and provides strong evidence that rational modification of this moiety can significantly enhance bioactivity.
Mandal et al. (2026) studied this question.